263 related articles for article (PubMed ID: 27687248)
1. Low expression of galectin-3 is associated with poor survival in node-positive breast cancers and mesenchymal phenotype in breast cancer stem cells.
Ilmer M; Mazurek N; Gilcrease MZ; Byrd JC; Woodward WA; Buchholz TA; Acklin K; Ramirez K; Hafley M; Alt E; Vykoukal J; Bresalier RS
Breast Cancer Res; 2016 Sep; 18(1):97. PubMed ID: 27687248
[TBL] [Abstract][Full Text] [Related]
2. Cell surface galectin-3 defines a subset of chemoresistant gastrointestinal tumor-initiating cancer cells with heightened stem cell characteristics.
Ilmer M; Mazurek N; Byrd JC; Ramirez K; Hafley M; Alt E; Vykoukal J; Bresalier RS
Cell Death Dis; 2016 Aug; 7(8):e2337. PubMed ID: 27512958
[TBL] [Abstract][Full Text] [Related]
3. High B3GALT5 expression confers poor clinical outcome and contributes to tumor progression and metastasis in breast cancer.
Liao YM; Wang YH; Hung JT; Lin YJ; Huang YL; Liao GS; Hsu YL; Wu JC; Yu AL
Breast Cancer Res; 2021 Jan; 23(1):5. PubMed ID: 33413566
[TBL] [Abstract][Full Text] [Related]
4. Long non-coding RNA LUCAT1/miR-5582-3p/TCF7L2 axis regulates breast cancer stemness via Wnt/β-catenin pathway.
Zheng A; Song X; Zhang L; Zhao L; Mao X; Wei M; Jin F
J Exp Clin Cancer Res; 2019 Jul; 38(1):305. PubMed ID: 31300015
[TBL] [Abstract][Full Text] [Related]
5. Metalloprotease-disintegrin ADAM12 actively promotes the stem cell-like phenotype in claudin-low breast cancer.
Duhachek-Muggy S; Qi Y; Wise R; Alyahya L; Li H; Hodge J; Zolkiewska A
Mol Cancer; 2017 Feb; 16(1):32. PubMed ID: 28148288
[TBL] [Abstract][Full Text] [Related]
6. Abnormally elevated USP37 expression in breast cancer stem cells regulates stemness, epithelial-mesenchymal transition and cisplatin sensitivity.
Qin T; Li B; Feng X; Fan S; Liu L; Liu D; Mao J; Lu Y; Yang J; Yu X; Zhang Q; Zhang J; Song B; Li M; Li L
J Exp Clin Cancer Res; 2018 Nov; 37(1):287. PubMed ID: 30482232
[TBL] [Abstract][Full Text] [Related]
7. Selective mode of action of plumbagin through BRCA1 deficient breast cancer stem cells.
Somasundaram V; Hemalatha SK; Pal K; Sinha S; Nair AS; Mukhopadhyay D; Srinivas P
BMC Cancer; 2016 May; 16():336. PubMed ID: 27229859
[TBL] [Abstract][Full Text] [Related]
8. Bmi1 regulates self-renewal and epithelial to mesenchymal transition in breast cancer cells through Nanog.
Paranjape AN; Balaji SA; Mandal T; Krushik EV; Nagaraj P; Mukherjee G; Rangarajan A
BMC Cancer; 2014 Oct; 14():785. PubMed ID: 25348805
[TBL] [Abstract][Full Text] [Related]
9. The expression and significance of insulin-like growth factor-1 receptor and its pathway on breast cancer stem/progenitors.
Chang WW; Lin RJ; Yu J; Chang WY; Fu CH; Lai A; Yu JC; Yu AL
Breast Cancer Res; 2013 May; 15(3):R39. PubMed ID: 23663564
[TBL] [Abstract][Full Text] [Related]
10. Knockdown of XB130 restrains cancer stem cell-like phenotype through inhibition of Wnt/β-Catenin signaling in breast cancer.
Xie T; Jiang C; Dai T; Xu R; Zhou X; Su X; Zhao X
Mol Carcinog; 2019 Oct; 58(10):1832-1845. PubMed ID: 31219645
[TBL] [Abstract][Full Text] [Related]
11. Reversal of epithelial-mesenchymal transition and inhibition of tumor stemness of breast cancer cells through advanced combined chemotherapy.
Cui Y; Zhao M; Yang Y; Xu R; Tong L; Liang J; Zhang X; Sun Y; Fan Y
Acta Biomater; 2022 Oct; 152():380-392. PubMed ID: 36028199
[TBL] [Abstract][Full Text] [Related]
12. RUNX1 and RUNX2 transcription factors function in opposing roles to regulate breast cancer stem cells.
Fritz AJ; Hong D; Boyd J; Kost J; Finstaad KH; Fitzgerald MP; Hanna S; Abuarqoub AH; Malik M; Bushweller J; Tye C; Ghule P; Gordon J; Frietze S; Zaidi SK; Lian JB; Stein JL; Stein GS
J Cell Physiol; 2020 Oct; 235(10):7261-7272. PubMed ID: 32180230
[TBL] [Abstract][Full Text] [Related]
13. Hsp27 participates in the maintenance of breast cancer stem cells through regulation of epithelial-mesenchymal transition and nuclear factor-κB.
Wei L; Liu TT; Wang HH; Hong HM; Yu AL; Feng HP; Chang WW
Breast Cancer Res; 2011 Oct; 13(5):R101. PubMed ID: 22023707
[TBL] [Abstract][Full Text] [Related]
14. Friend leukemia virus integration 1 is a predictor of poor prognosis of breast cancer and promotes metastasis and cancer stem cell properties of breast cancer cells.
Yan X; Yu Y; Li L; Chen N; Song W; He H; Dong J; Liu X; Cui J
Cancer Med; 2018 Aug; 7(8):3548-3560. PubMed ID: 29869379
[TBL] [Abstract][Full Text] [Related]
15. Hypoxia promotes the phenotypic change of aldehyde dehydrogenase activity of breast cancer stem cells.
Shiraishi A; Tachi K; Essid N; Tsuboi I; Nagano M; Kato T; Yamashita T; Bando H; Hara H; Ohneda O
Cancer Sci; 2017 Mar; 108(3):362-372. PubMed ID: 28012234
[TBL] [Abstract][Full Text] [Related]
16. Nestin positively regulates the Wnt/β-catenin pathway and the proliferation, survival and invasiveness of breast cancer stem cells.
Zhao Z; Lu P; Zhang H; Xu H; Gao N; Li M; Liu C
Breast Cancer Res; 2014 Jul; 16(4):408. PubMed ID: 25056574
[TBL] [Abstract][Full Text] [Related]
17. The T-box transcription factor Brachyury regulates epithelial-mesenchymal transition in association with cancer stem-like cells in adenoid cystic carcinoma cells.
Shimoda M; Sugiura T; Imajyo I; Ishii K; Chigita S; Seki K; Kobayashi Y; Shirasuna K
BMC Cancer; 2012 Aug; 12():377. PubMed ID: 22931165
[TBL] [Abstract][Full Text] [Related]
18. Aryl hydrocarbon receptor/cytochrome P450 1A1 pathway mediates breast cancer stem cells expansion through PTEN inhibition and β-Catenin and Akt activation.
Al-Dhfyan A; Alhoshani A; Korashy HM
Mol Cancer; 2017 Jan; 16(1):14. PubMed ID: 28103884
[TBL] [Abstract][Full Text] [Related]
19. Expression of Six1 in luminal breast cancers predicts poor prognosis and promotes increases in tumor initiating cells by activation of extracellular signal-regulated kinase and transforming growth factor-beta signaling pathways.
Iwanaga R; Wang CA; Micalizzi DS; Harrell JC; Jedlicka P; Sartorius CA; Kabos P; Farabaugh SM; Bradford AP; Ford HL
Breast Cancer Res; 2012 Jul; 14(4):R100. PubMed ID: 22765220
[TBL] [Abstract][Full Text] [Related]
20. Suppression of apoptosis inhibitor c-FLIP selectively eliminates breast cancer stem cell activity in response to the anti-cancer agent, TRAIL.
Piggott L; Omidvar N; Martí Pérez S; French R; Eberl M; Clarkson RW
Breast Cancer Res; 2011 Sep; 13(5):R88. PubMed ID: 21914219
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
